Veracyte, Inc. (VCYT)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Veracyte, Inc. keeps $17 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 11 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Veracyte beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported July 30, as revenue of about $150.3 million topped the roughly $144.6 million consensus by 4.0%, and adjusted EPS of $0.54 beat the $0.41 estimate by 31.6%. Revenue rose 15.5% from about $130.2 million a year ago, with gross margin at 72.2% and operating margin at 15.3%. Net income climbed to about $25.5 million from a loss of $980,000 a year earlier, and adjusted EPS was up 22.7% from $0.44. The company generated operating cash flow of about $45.8 million and repurchased about $4.3 million of stock, and next-period consensus calls for EPS of $0.44 on revenue of $147.1 million.
Next report — what to expect
Veracyte, Inc. (VCYT) is scheduled to report earnings on November 3, 2026. Wall Street consensus calls for EPS of $0.43 on revenue of $147.2 million. For trailing context, revenue grew +15.5% year over year last quarter. Veracyte has beaten EPS in 7 of 8 most recent quarters.
About Veracyte, Inc.
Veracyte, Inc. (NASDAQ:VCYT) is a healthcare diagnostics company that develops genomic tests for cancer diagnosis and related analysis services. Its business sits in medical diagnostics and research, centered on tests that guide clinical decisions, and it generated $517.1 million of revenue in FY2025.
Today's Snapshot
VCYT closed 4.1% higher at 47.93, outperforming a weaker sector. Veracyte reported its Decipher prostate test predicted which patients benefited from added abiraterone. VCYT is due to report earnings on 4 November.
Trading Volume
Below 10d avg (1.1M)
905.9K
vs S&P 500 Today
Strong Outperformance
+4.63%
Updated: October 23, 2026 at 20:27 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$42.84 - $45.35Buy
- RSI (14)60.09Neutral
- Stochastic %K (14, 3, 3)72.31Neutral
- MACD Level (12, 26)0.49Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.